Related Experiment Video
Updated: Apr 7, 2026
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
Impact of IL-1 inhibition on fatigue associated with autoinflammatory syndromes
Sujani Yadlapati1, Petros Efthimiou2
1a Associate chief, Rheumatology Division, New York Methodist Hospital , Brooklyn , NY , USA.
Abstract:
Cryopyrin-associated periodic syndromes (CAPS) is a rare group of autoinflammatory disorders that includes familial cold autoinflammatory syndrome or FCAS, Muckle-wells syndrome or MWS, and neonatal-onset multisystem inflammatory disease or NOMID. CAPS is caused by a mutation in the NOD-like receptor family, pyrin domain containing 3 (NLRP3) gene. This ultimately leads to increased production of interleukin (IL)-1β. IL-1β is a biologically active member of the IL-1 family. It is not only a pro-inflammatory cytokine responsible for features such as fever, rash, and arthritis, but is also a major mediator in the central pathways of fatigue. Fatigue is a major component of CAPS and is associated with severely compromised quality of life. In clinical studies, fatigue was measured using functional assessment of chronic illness therapy-fatigue or FACIT-F and short form-36 or SF-36, physical component score instruments. These questionnaires can also be used to monitor improvement of fatigue following initiation of therapy. IL-1 inhibitors block the IL-1 signaling cascade, thereby preventing systemic inflammation in CAPS. The decrease in systemic inflammation is accompanied by improvement in fatigue.
Insights
Cryopyrin-associated periodic syndromes (CAPS) are rare autoinflammatory disorders caused by NLRP3 gene mutations. Blocking IL-1β with IL-1 inhibitors effectively reduces inflammation and improves fatigue in CAPS patients.
Area of Science:
- Immunology
- Genetics
- Rheumatology
Background:
- Cryopyrin-associated periodic syndromes (CAPS) encompass rare autoinflammatory disorders including FCAS, MWS, and NOMID.
- These conditions stem from mutations in the NLRP3 gene, leading to elevated interleukin-1 beta (IL-1β) production.
- IL-1β is a key pro-inflammatory cytokine implicated in fever, rash, arthritis, and central fatigue pathways.
Purpose of the Study:
- To investigate the role of IL-1β in mediating fatigue in CAPS.
- To evaluate the efficacy of IL-1 inhibitors in managing CAPS-related fatigue.
- To highlight the utility of FACIT-F and SF-36 questionnaires in assessing fatigue in CAPS.
Main Methods:
- Review of clinical studies measuring fatigue using FACIT-F and SF-36 instruments.
- Analysis of the mechanism of action of IL-1 inhibitors in blocking the IL-1 signaling cascade.
- Correlation of systemic inflammation reduction with fatigue improvement.
Main Results:
- IL-1β is a significant mediator of fatigue in CAPS, impacting quality of life.
- IL-1 inhibitors effectively block IL-1 signaling, reducing systemic inflammation.
- Therapeutic blockade of IL-1 leads to a measurable improvement in fatigue levels.
Conclusions:
- Targeting IL-1β with inhibitors is a viable therapeutic strategy for CAPS.
- IL-1 inhibition successfully alleviates systemic inflammation and associated fatigue in CAPS patients.
- FACIT-F and SF-36 are valuable tools for monitoring treatment response in CAPS fatigue.
More Related Videos
Related Concept Videos
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20The JAK-STAT Signaling Pathway
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:28Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:30Inhibitors of Viral Protein Synthesis
01:29Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...